Announcements Trials
Browse Landscape

Phase

Phase 1 8Phase 2 6Phase 1/2 5Phase 3 4Phase EARLY_PHASE1 1

Status

Recruiting 81Unknown 76Not yet recruiting 54Completed 37Active not recruiting 17Terminated 6Withdrawn 5

Sponsor Class

INDUSTRY 4OTHER_GOV 1OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Dermatologic 1

Conditions

Stomach Neoplasms 1Neoplasms 1Melanoma 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 144Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 2 × Terminated × tislelizumab × Clear all
NCT06897579 2026-04-28

Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Terminated
40 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

NCT04363801 2025-10-09

DisTinGuish

Leap Therapeutics, Inc.

Phase 2 Terminated
247 enrolled 38 charts
Gastrointestinal

Adenocarcinoma, Neoplasms, Stomach Neoplasms

NCT05461794 2025-06-13

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

BeiGene

Phase 2 Terminated
96 enrolled 17 charts
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04952753 2025-03-26

daNIS-3

Novartis

Phase 2 Terminated
204 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT04924413 2024-07-03

L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma

Henan Cancer Hospital

Phase 2 Terminated
9 enrolled
Dermatologic

Melanoma

NCT05176925 2024-01-29

Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC

Fudan University

Phase 2 Terminated
5 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡